Global Live Attenuated Polio Vaccine Market Growth 2026-2032
The global Live Attenuated Polio Vaccine market size is predicted to grow from US$ 230 million in 2025 to US$ 270 million in 2032; it is expected to grow at a CAGR of 2.3% from 2026 to 2032.
Live Attenuated Polio Vaccine is an oral preventive biological product produced from artificially attenuated poliovirus strains through viral culture, harvest, purification or clarification, stabilizer formulation, and filling. By mimicking natural intestinal infection, it induces both humoral immunity and intestinal mucosal immunity, helping prevent poliomyelitis infection and interrupt virus transmission within populations. Depending on the virus types included, it can be classified as trivalent, bivalent, or monovalent oral polio vaccine. Its use strategy changes across different stages of global polio eradication, depending on wild poliovirus circulation, vaccine-derived poliovirus risks, and immunization program adjustments. Compared with inactivated vaccines, live attenuated polio vaccines offer convenient oral administration, strong herd-immunity effects, and suitability for large-scale emergency campaigns and transmission interruption, making them one of the most influential vaccine categories in the history of global polio control.In 2025, global Live Attenuated Polio Vaccine production reached approximately 200 million doses.The average gross profit margin of this product is 55%.
The market value of live attenuated polio vaccines mainly comes from transmission interruption needs in the final stage of global polio eradication, immunization accessibility in developing countries, and public health emergency preparedness. OPV offers oral administration, ease of use, suitability for mass population coverage, and strong intestinal mucosal immunity. In regions where wild poliovirus transmission or vaccine-derived poliovirus outbreaks remain a risk, it continues to be an important tool for rapidly building community protection. WHO?s prequalification of novel oral polio vaccine type 2 shows that the global market is not simply abandoning OPV, but optimizing its emergency-use value through improved genetic stability and safety. For manufacturers, live attenuated polio vaccine is not merely a low-price public health product, but a strategic category connected to national immunization programs, international organization procurement, outbreak response, and the global polio eradication agenda.
The core challenges of this industry lie in safety pressure during the post-eradication stage, shrinking routine-use scenarios, and higher regulatory requirements. OPV contains live attenuated virus. Although it has strong advantages in herd immunity and transmission interruption, in areas with low immunization coverage, vaccine strains may circulate for extended periods and accumulate genetic changes. As a result, global immunization strategies are gradually shifting from broad reliance on OPV toward staged and scenario-specific coordination between IPV and OPV. China CDC documents also show that immunization schedules emphasize sequential use of IPV and bOPV rather than reliance on OPV alone. Manufacturers must maintain high standards in strain genetic stability, viral titer control, stabilizer systems, cold-chain storage and transportation, batch release, and post-marketing safety monitoring, while facing demand-structure changes and capacity utilization uncertainty caused by policy adjustments.
Downstream demand is shifting from broad routine use toward sequential use in immunization programs, supplementary immunization in key regions, outbreak response, and international public health procurement. Disease control systems focus on whether products can rapidly cover large populations, interrupt fecal-oral transmission chains, and coordinate effectively with IPV-based schedules. International organizations and developing-country markets place greater emphasis on supply stability, affordability, cold-chain adaptability, and field vaccination efficiency. As global polio control enters a more refined stage, routine demand for traditional OPV may gradually decline, but novel and more stable OPV products will retain critical value in localized outbreak control and public health emergency response. Future competitiveness will increasingly be reflected in public health response capability, international certification, and global supply chain coordination.
LP Information, Inc. (LPI) ' newest research report, the ?Live Attenuated Polio Vaccine Industry Forecast? looks at past sales and reviews total world Live Attenuated Polio Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Live Attenuated Polio Vaccine sales for 2026 through 2032. With Live Attenuated Polio Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Polio Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Live Attenuated Polio Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Polio Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live Attenuated Polio Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Polio Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Polio Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Polio Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Live Attenuated Polio Vaccine market?
What factors are driving Live Attenuated Polio Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Live Attenuated Polio Vaccine market opportunities vary by end market size?
How does Live Attenuated Polio Vaccine break out by Type, by Application?
Live Attenuated Polio Vaccine is an oral preventive biological product produced from artificially attenuated poliovirus strains through viral culture, harvest, purification or clarification, stabilizer formulation, and filling. By mimicking natural intestinal infection, it induces both humoral immunity and intestinal mucosal immunity, helping prevent poliomyelitis infection and interrupt virus transmission within populations. Depending on the virus types included, it can be classified as trivalent, bivalent, or monovalent oral polio vaccine. Its use strategy changes across different stages of global polio eradication, depending on wild poliovirus circulation, vaccine-derived poliovirus risks, and immunization program adjustments. Compared with inactivated vaccines, live attenuated polio vaccines offer convenient oral administration, strong herd-immunity effects, and suitability for large-scale emergency campaigns and transmission interruption, making them one of the most influential vaccine categories in the history of global polio control.In 2025, global Live Attenuated Polio Vaccine production reached approximately 200 million doses.The average gross profit margin of this product is 55%.
The market value of live attenuated polio vaccines mainly comes from transmission interruption needs in the final stage of global polio eradication, immunization accessibility in developing countries, and public health emergency preparedness. OPV offers oral administration, ease of use, suitability for mass population coverage, and strong intestinal mucosal immunity. In regions where wild poliovirus transmission or vaccine-derived poliovirus outbreaks remain a risk, it continues to be an important tool for rapidly building community protection. WHO?s prequalification of novel oral polio vaccine type 2 shows that the global market is not simply abandoning OPV, but optimizing its emergency-use value through improved genetic stability and safety. For manufacturers, live attenuated polio vaccine is not merely a low-price public health product, but a strategic category connected to national immunization programs, international organization procurement, outbreak response, and the global polio eradication agenda.
The core challenges of this industry lie in safety pressure during the post-eradication stage, shrinking routine-use scenarios, and higher regulatory requirements. OPV contains live attenuated virus. Although it has strong advantages in herd immunity and transmission interruption, in areas with low immunization coverage, vaccine strains may circulate for extended periods and accumulate genetic changes. As a result, global immunization strategies are gradually shifting from broad reliance on OPV toward staged and scenario-specific coordination between IPV and OPV. China CDC documents also show that immunization schedules emphasize sequential use of IPV and bOPV rather than reliance on OPV alone. Manufacturers must maintain high standards in strain genetic stability, viral titer control, stabilizer systems, cold-chain storage and transportation, batch release, and post-marketing safety monitoring, while facing demand-structure changes and capacity utilization uncertainty caused by policy adjustments.
Downstream demand is shifting from broad routine use toward sequential use in immunization programs, supplementary immunization in key regions, outbreak response, and international public health procurement. Disease control systems focus on whether products can rapidly cover large populations, interrupt fecal-oral transmission chains, and coordinate effectively with IPV-based schedules. International organizations and developing-country markets place greater emphasis on supply stability, affordability, cold-chain adaptability, and field vaccination efficiency. As global polio control enters a more refined stage, routine demand for traditional OPV may gradually decline, but novel and more stable OPV products will retain critical value in localized outbreak control and public health emergency response. Future competitiveness will increasingly be reflected in public health response capability, international certification, and global supply chain coordination.
LP Information, Inc. (LPI) ' newest research report, the ?Live Attenuated Polio Vaccine Industry Forecast? looks at past sales and reviews total world Live Attenuated Polio Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Live Attenuated Polio Vaccine sales for 2026 through 2032. With Live Attenuated Polio Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Polio Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Live Attenuated Polio Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Polio Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live Attenuated Polio Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Polio Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Polio Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Polio Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Conventional OPV
- Novel OPV
- Monovalent
- Bivalent
- Trivalent
- Oral Drops
- Sugar Pill
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- GSK
- Bibcol
- Serum Institute (Bilthoven Biologicals)
- Tiantan Biological
- IMBCA
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
What is the 10-year outlook for the global Live Attenuated Polio Vaccine market?
What factors are driving Live Attenuated Polio Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Live Attenuated Polio Vaccine market opportunities vary by end market size?
How does Live Attenuated Polio Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Live Attenuated Polio Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Live Attenuated Polio Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Live Attenuated Polio Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Live Attenuated Polio Vaccine Segment by Type
2.2.1 Conventional OPV
2.2.2 Novel OPV
2.2.3 Live Attenuated Polio Vaccine Sales by Type
2.2.3.1 Global Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Live Attenuated Polio Vaccine Sale Price by Type (2021-2026)
2.3 Live Attenuated Polio Vaccine Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Live Attenuated Polio Vaccine Sales by Virus Type
2.3.4.1 Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Live Attenuated Polio Vaccine Sale Price by Virus Type (2021-2026)
2.4 Live Attenuated Polio Vaccine Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Live Attenuated Polio Vaccine Sales by Dosage Form
2.4.3.1 Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Live Attenuated Polio Vaccine Sale Price by Dosage Form (2021-2026)
2.5 Live Attenuated Polio Vaccine Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Live Attenuated Polio Vaccine Sales by Application
2.5.4.1 Global Live Attenuated Polio Vaccine Sale Market Share by Application (2021-2026)
2.5.4.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Live Attenuated Polio Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Live Attenuated Polio Vaccine Breakdown Data by Company
3.1.1 Global Live Attenuated Polio Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Live Attenuated Polio Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Live Attenuated Polio Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Live Attenuated Polio Vaccine Revenue by Company (2021-2026)
3.2.2 Global Live Attenuated Polio Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Live Attenuated Polio Vaccine Sale Price by Company
3.4 Key Manufacturers Live Attenuated Polio Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live Attenuated Polio Vaccine Product Location Distribution
3.4.2 Players Live Attenuated Polio Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIVE ATTENUATED POLIO VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Live Attenuated Polio Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Live Attenuated Polio Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Live Attenuated Polio Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Live Attenuated Polio Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Live Attenuated Polio Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Live Attenuated Polio Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Live Attenuated Polio Vaccine Sales Growth
4.4 APAC Live Attenuated Polio Vaccine Sales Growth
4.5 Europe Live Attenuated Polio Vaccine Sales Growth
4.6 Middle East & Africa Live Attenuated Polio Vaccine Sales Growth
5 AMERICAS
5.1 Americas Live Attenuated Polio Vaccine Sales by Country
5.1.1 Americas Live Attenuated Polio Vaccine Sales by Country (2021-2026)
5.1.2 Americas Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
5.2 Americas Live Attenuated Polio Vaccine Sales by Type (2021-2026)
5.3 Americas Live Attenuated Polio Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live Attenuated Polio Vaccine Sales by Region
6.1.1 APAC Live Attenuated Polio Vaccine Sales by Region (2021-2026)
6.1.2 APAC Live Attenuated Polio Vaccine Revenue by Region (2021-2026)
6.2 APAC Live Attenuated Polio Vaccine Sales by Type (2021-2026)
6.3 APAC Live Attenuated Polio Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Live Attenuated Polio Vaccine by Country
7.1.1 Europe Live Attenuated Polio Vaccine Sales by Country (2021-2026)
7.1.2 Europe Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
7.2 Europe Live Attenuated Polio Vaccine Sales by Type (2021-2026)
7.3 Europe Live Attenuated Polio Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Live Attenuated Polio Vaccine by Country
8.1.1 Middle East & Africa Live Attenuated Polio Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Live Attenuated Polio Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Live Attenuated Polio Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live Attenuated Polio Vaccine
10.3 Manufacturing Process Analysis of Live Attenuated Polio Vaccine
10.4 Industry Chain Structure of Live Attenuated Polio Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live Attenuated Polio Vaccine Distributors
11.3 Live Attenuated Polio Vaccine Customer
12 WORLD FORECAST REVIEW FOR LIVE ATTENUATED POLIO VACCINE BY GEOGRAPHIC REGION
12.1 Global Live Attenuated Polio Vaccine Market Size Forecast by Region
12.1.1 Global Live Attenuated Polio Vaccine Forecast by Region (2027-2032)
12.1.2 Global Live Attenuated Polio Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Live Attenuated Polio Vaccine Forecast by Type (2027-2032)
12.7 Global Live Attenuated Polio Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.2.3 GSK Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.3.3 Bibcol Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.5.3 Tiantan Biological Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.6.3 IMBCA Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.8.3 Bio-Med Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Live Attenuated Polio Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Live Attenuated Polio Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Live Attenuated Polio Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Live Attenuated Polio Vaccine Segment by Type
2.2.1 Conventional OPV
2.2.2 Novel OPV
2.2.3 Live Attenuated Polio Vaccine Sales by Type
2.2.3.1 Global Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Live Attenuated Polio Vaccine Sale Price by Type (2021-2026)
2.3 Live Attenuated Polio Vaccine Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Live Attenuated Polio Vaccine Sales by Virus Type
2.3.4.1 Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Live Attenuated Polio Vaccine Sale Price by Virus Type (2021-2026)
2.4 Live Attenuated Polio Vaccine Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Live Attenuated Polio Vaccine Sales by Dosage Form
2.4.3.1 Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Live Attenuated Polio Vaccine Sale Price by Dosage Form (2021-2026)
2.5 Live Attenuated Polio Vaccine Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Live Attenuated Polio Vaccine Sales by Application
2.5.4.1 Global Live Attenuated Polio Vaccine Sale Market Share by Application (2021-2026)
2.5.4.2 Global Live Attenuated Polio Vaccine Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Live Attenuated Polio Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Live Attenuated Polio Vaccine Breakdown Data by Company
3.1.1 Global Live Attenuated Polio Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Live Attenuated Polio Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Live Attenuated Polio Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Live Attenuated Polio Vaccine Revenue by Company (2021-2026)
3.2.2 Global Live Attenuated Polio Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Live Attenuated Polio Vaccine Sale Price by Company
3.4 Key Manufacturers Live Attenuated Polio Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live Attenuated Polio Vaccine Product Location Distribution
3.4.2 Players Live Attenuated Polio Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIVE ATTENUATED POLIO VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Live Attenuated Polio Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Live Attenuated Polio Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Live Attenuated Polio Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Live Attenuated Polio Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Live Attenuated Polio Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Live Attenuated Polio Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Live Attenuated Polio Vaccine Sales Growth
4.4 APAC Live Attenuated Polio Vaccine Sales Growth
4.5 Europe Live Attenuated Polio Vaccine Sales Growth
4.6 Middle East & Africa Live Attenuated Polio Vaccine Sales Growth
5 AMERICAS
5.1 Americas Live Attenuated Polio Vaccine Sales by Country
5.1.1 Americas Live Attenuated Polio Vaccine Sales by Country (2021-2026)
5.1.2 Americas Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
5.2 Americas Live Attenuated Polio Vaccine Sales by Type (2021-2026)
5.3 Americas Live Attenuated Polio Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live Attenuated Polio Vaccine Sales by Region
6.1.1 APAC Live Attenuated Polio Vaccine Sales by Region (2021-2026)
6.1.2 APAC Live Attenuated Polio Vaccine Revenue by Region (2021-2026)
6.2 APAC Live Attenuated Polio Vaccine Sales by Type (2021-2026)
6.3 APAC Live Attenuated Polio Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Live Attenuated Polio Vaccine by Country
7.1.1 Europe Live Attenuated Polio Vaccine Sales by Country (2021-2026)
7.1.2 Europe Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
7.2 Europe Live Attenuated Polio Vaccine Sales by Type (2021-2026)
7.3 Europe Live Attenuated Polio Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Live Attenuated Polio Vaccine by Country
8.1.1 Middle East & Africa Live Attenuated Polio Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Live Attenuated Polio Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Live Attenuated Polio Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Live Attenuated Polio Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live Attenuated Polio Vaccine
10.3 Manufacturing Process Analysis of Live Attenuated Polio Vaccine
10.4 Industry Chain Structure of Live Attenuated Polio Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live Attenuated Polio Vaccine Distributors
11.3 Live Attenuated Polio Vaccine Customer
12 WORLD FORECAST REVIEW FOR LIVE ATTENUATED POLIO VACCINE BY GEOGRAPHIC REGION
12.1 Global Live Attenuated Polio Vaccine Market Size Forecast by Region
12.1.1 Global Live Attenuated Polio Vaccine Forecast by Region (2027-2032)
12.1.2 Global Live Attenuated Polio Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Live Attenuated Polio Vaccine Forecast by Type (2027-2032)
12.7 Global Live Attenuated Polio Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.2.3 GSK Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.3.3 Bibcol Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.5.3 Tiantan Biological Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.6.3 IMBCA Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.8.3 Bio-Med Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Live Attenuated Polio Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Live Attenuated Polio Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional OPV
Table 4. Major Players of Novel OPV
Table 5. Global Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 6. Global Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Live Attenuated Polio Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Live Attenuated Polio Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Live Attenuated Polio Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Live Attenuated Polio Vaccine Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type (2021-2026)
Table 15. Global Live Attenuated Polio Vaccine Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Live Attenuated Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Live Attenuated Polio Vaccine Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Global Live Attenuated Polio Vaccine Sales by Dosage Form (2021-2026) & (K Dose)
Table 21. Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Live Attenuated Polio Vaccine Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Live Attenuated Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Live Attenuated Polio Vaccine Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 25. Global Live Attenuated Polio Vaccine Sale by Application (2021-2026) & (K Dose)
Table 26. Global Live Attenuated Polio Vaccine Sale Market Share by Application (2021-2026)
Table 27. Global Live Attenuated Polio Vaccine Revenue by Application (2021-2026) & ($ million)
Table 28. Global Live Attenuated Polio Vaccine Revenue Market Share by Application (2021-2026)
Table 29. Global Live Attenuated Polio Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Live Attenuated Polio Vaccine Sales by Company (2021-2026) & (K Dose)
Table 31. Global Live Attenuated Polio Vaccine Sales Market Share by Company (2021-2026)
Table 32. Global Live Attenuated Polio Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Live Attenuated Polio Vaccine Revenue Market Share by Company (2021-2026)
Table 34. Global Live Attenuated Polio Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Live Attenuated Polio Vaccine Producing Area Distribution and Sales Area
Table 36. Players Live Attenuated Polio Vaccine Products Offered
Table 37. Live Attenuated Polio Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Live Attenuated Polio Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Live Attenuated Polio Vaccine Sales Market Share Geographic Region (2021-2026)
Table 42. Global Live Attenuated Polio Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Live Attenuated Polio Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Live Attenuated Polio Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2021-2026)
Table 46. Global Live Attenuated Polio Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Live Attenuated Polio Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Live Attenuated Polio Vaccine Sales Market Share by Country (2021-2026)
Table 50. Americas Live Attenuated Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Live Attenuated Polio Vaccine Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Live Attenuated Polio Vaccine Sales Market Share by Region (2021-2026)
Table 55. APAC Live Attenuated Polio Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Live Attenuated Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Live Attenuated Polio Vaccine
Table 67. Key Market Challenges & Risks of Live Attenuated Polio Vaccine
Table 68. Key Industry Trends of Live Attenuated Polio Vaccine
Table 69. Live Attenuated Polio Vaccine Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Live Attenuated Polio Vaccine Distributors List
Table 72. Live Attenuated Polio Vaccine Customer List
Table 73. Global Live Attenuated Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Live Attenuated Polio Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Live Attenuated Polio Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Live Attenuated Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Live Attenuated Polio Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Live Attenuated Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Live Attenuated Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Live Attenuated Polio Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Live Attenuated Polio Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Live Attenuated Polio Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Live Attenuated Polio Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Sanofi Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 89. Sanofi Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Sanofi Main Business
Table 91. Sanofi Latest Developments
Table 92. GSK Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 94. GSK Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Bibcol Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Bibcol Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 99. Bibcol Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Bibcol Main Business
Table 101. Bibcol Latest Developments
Table 102. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Serum?Institute?(Bilthoven?Biologicals) Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 104. Serum?Institute?(Bilthoven?Biologicals) Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 106. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 107. Tiantan Biological Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Tiantan Biological Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 109. Tiantan Biological Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Tiantan Biological Main Business
Table 111. Tiantan Biological Latest Developments
Table 112. IMBCA Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. IMBCA Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 114. IMBCA Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. IMBCA Main Business
Table 116. IMBCA Latest Developments
Table 117. Panacea Biotec Ltd Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Panacea Biotec Ltd Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 119. Panacea Biotec Ltd Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Panacea Biotec Ltd Main Business
Table 121. Panacea Biotec Ltd Latest Developments
Table 122. Bio-Med Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Med Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 124. Bio-Med Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Med Main Business
Table 126. Bio-Med Latest Developments
Table 127. Halfkin Bio-Pharmaceuticals Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 129. Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Halfkin Bio-Pharmaceuticals Main Business
Table 131. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Live Attenuated Polio Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Live Attenuated Polio Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional OPV
Table 4. Major Players of Novel OPV
Table 5. Global Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 6. Global Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Live Attenuated Polio Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Live Attenuated Polio Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Live Attenuated Polio Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Live Attenuated Polio Vaccine Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type (2021-2026)
Table 15. Global Live Attenuated Polio Vaccine Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Live Attenuated Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Live Attenuated Polio Vaccine Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Global Live Attenuated Polio Vaccine Sales by Dosage Form (2021-2026) & (K Dose)
Table 21. Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Live Attenuated Polio Vaccine Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Live Attenuated Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Live Attenuated Polio Vaccine Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 25. Global Live Attenuated Polio Vaccine Sale by Application (2021-2026) & (K Dose)
Table 26. Global Live Attenuated Polio Vaccine Sale Market Share by Application (2021-2026)
Table 27. Global Live Attenuated Polio Vaccine Revenue by Application (2021-2026) & ($ million)
Table 28. Global Live Attenuated Polio Vaccine Revenue Market Share by Application (2021-2026)
Table 29. Global Live Attenuated Polio Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Live Attenuated Polio Vaccine Sales by Company (2021-2026) & (K Dose)
Table 31. Global Live Attenuated Polio Vaccine Sales Market Share by Company (2021-2026)
Table 32. Global Live Attenuated Polio Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Live Attenuated Polio Vaccine Revenue Market Share by Company (2021-2026)
Table 34. Global Live Attenuated Polio Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Live Attenuated Polio Vaccine Producing Area Distribution and Sales Area
Table 36. Players Live Attenuated Polio Vaccine Products Offered
Table 37. Live Attenuated Polio Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Live Attenuated Polio Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Live Attenuated Polio Vaccine Sales Market Share Geographic Region (2021-2026)
Table 42. Global Live Attenuated Polio Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Live Attenuated Polio Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Live Attenuated Polio Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2021-2026)
Table 46. Global Live Attenuated Polio Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Live Attenuated Polio Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Live Attenuated Polio Vaccine Sales Market Share by Country (2021-2026)
Table 50. Americas Live Attenuated Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Live Attenuated Polio Vaccine Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Live Attenuated Polio Vaccine Sales Market Share by Region (2021-2026)
Table 55. APAC Live Attenuated Polio Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Live Attenuated Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Live Attenuated Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Live Attenuated Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Live Attenuated Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Live Attenuated Polio Vaccine
Table 67. Key Market Challenges & Risks of Live Attenuated Polio Vaccine
Table 68. Key Industry Trends of Live Attenuated Polio Vaccine
Table 69. Live Attenuated Polio Vaccine Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Live Attenuated Polio Vaccine Distributors List
Table 72. Live Attenuated Polio Vaccine Customer List
Table 73. Global Live Attenuated Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Live Attenuated Polio Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Live Attenuated Polio Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Live Attenuated Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Live Attenuated Polio Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Live Attenuated Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Live Attenuated Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Live Attenuated Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Live Attenuated Polio Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Live Attenuated Polio Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Live Attenuated Polio Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Live Attenuated Polio Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Sanofi Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 89. Sanofi Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Sanofi Main Business
Table 91. Sanofi Latest Developments
Table 92. GSK Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 94. GSK Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Bibcol Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Bibcol Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 99. Bibcol Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Bibcol Main Business
Table 101. Bibcol Latest Developments
Table 102. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Serum?Institute?(Bilthoven?Biologicals) Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 104. Serum?Institute?(Bilthoven?Biologicals) Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 106. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 107. Tiantan Biological Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Tiantan Biological Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 109. Tiantan Biological Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Tiantan Biological Main Business
Table 111. Tiantan Biological Latest Developments
Table 112. IMBCA Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. IMBCA Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 114. IMBCA Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. IMBCA Main Business
Table 116. IMBCA Latest Developments
Table 117. Panacea Biotec Ltd Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Panacea Biotec Ltd Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 119. Panacea Biotec Ltd Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Panacea Biotec Ltd Main Business
Table 121. Panacea Biotec Ltd Latest Developments
Table 122. Bio-Med Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Med Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 124. Bio-Med Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Med Main Business
Table 126. Bio-Med Latest Developments
Table 127. Halfkin Bio-Pharmaceuticals Basic Information, Live Attenuated Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Product Portfolios and Specifications
Table 129. Halfkin Bio-Pharmaceuticals Live Attenuated Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Halfkin Bio-Pharmaceuticals Main Business
Table 131. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Live Attenuated Polio Vaccine
Figure 2. Live Attenuated Polio Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live Attenuated Polio Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Live Attenuated Polio Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Live Attenuated Polio Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional OPV
Figure 12. Product Picture of Novel OPV
Figure 13. Global Live Attenuated Polio Vaccine Sales Market Share by Type in 2026
Figure 14. Global Live Attenuated Polio Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type in 2026
Figure 19. Global Live Attenuated Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form in 2026
Figure 23. Global Live Attenuated Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Live Attenuated Polio Vaccine Consumed in Hospital
Figure 25. Global Live Attenuated Polio Vaccine Market: Hospital (2021-2026) & (K Dose)
Figure 26. Live Attenuated Polio Vaccine Consumed in Clinic
Figure 27. Global Live Attenuated Polio Vaccine Market: Clinic (2021-2026) & (K Dose)
Figure 28. Live Attenuated Polio Vaccine Consumed in Others
Figure 29. Global Live Attenuated Polio Vaccine Market: Others (2021-2026) & (K Dose)
Figure 30. Global Live Attenuated Polio Vaccine Sale Market Share by Application (2025)
Figure 31. Global Live Attenuated Polio Vaccine Revenue Market Share by Application in 2025
Figure 32. Live Attenuated Polio Vaccine Sales by Company in 2025 (K Dose)
Figure 33. Global Live Attenuated Polio Vaccine Sales Market Share by Company in 2025
Figure 34. Live Attenuated Polio Vaccine Revenue by Company in 2025 ($ millions)
Figure 35. Global Live Attenuated Polio Vaccine Revenue Market Share by Company in 2025
Figure 36. Global Live Attenuated Polio Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Live Attenuated Polio Vaccine Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 39. Americas Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 40. APAC Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 41. APAC Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 42. Europe Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 43. Europe Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 45. Middle East & Africa Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Americas Live Attenuated Polio Vaccine Sales Market Share by Country in 2025
Figure 47. Americas Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 48. Americas Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 49. Americas Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 50. United States Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Live Attenuated Polio Vaccine Sales Market Share by Region in 2025
Figure 55. APAC Live Attenuated Polio Vaccine Revenue Market Share by Region (2021-2026)
Figure 56. APAC Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 57. APAC Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 58. China Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. India Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Live Attenuated Polio Vaccine Sales Market Share by Country in 2025
Figure 66. Europe Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 67. Europe Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 68. Europe Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 69. Germany Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. France Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 77. Egypt Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Live Attenuated Polio Vaccine in 2026
Figure 83. Manufacturing Process Analysis of Live Attenuated Polio Vaccine
Figure 84. Industry Chain Structure of Live Attenuated Polio Vaccine
Figure 85. Channels of Distribution
Figure 86. Global Live Attenuated Polio Vaccine Sales Market Forecast by Region (2027-2032)
Figure 87. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Live Attenuated Polio Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Live Attenuated Polio Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Live Attenuated Polio Vaccine
Figure 2. Live Attenuated Polio Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live Attenuated Polio Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Live Attenuated Polio Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Live Attenuated Polio Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Live Attenuated Polio Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional OPV
Figure 12. Product Picture of Novel OPV
Figure 13. Global Live Attenuated Polio Vaccine Sales Market Share by Type in 2026
Figure 14. Global Live Attenuated Polio Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Live Attenuated Polio Vaccine Sales Market Share by Virus Type in 2026
Figure 19. Global Live Attenuated Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Global Live Attenuated Polio Vaccine Sales Market Share by Dosage Form in 2026
Figure 23. Global Live Attenuated Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Live Attenuated Polio Vaccine Consumed in Hospital
Figure 25. Global Live Attenuated Polio Vaccine Market: Hospital (2021-2026) & (K Dose)
Figure 26. Live Attenuated Polio Vaccine Consumed in Clinic
Figure 27. Global Live Attenuated Polio Vaccine Market: Clinic (2021-2026) & (K Dose)
Figure 28. Live Attenuated Polio Vaccine Consumed in Others
Figure 29. Global Live Attenuated Polio Vaccine Market: Others (2021-2026) & (K Dose)
Figure 30. Global Live Attenuated Polio Vaccine Sale Market Share by Application (2025)
Figure 31. Global Live Attenuated Polio Vaccine Revenue Market Share by Application in 2025
Figure 32. Live Attenuated Polio Vaccine Sales by Company in 2025 (K Dose)
Figure 33. Global Live Attenuated Polio Vaccine Sales Market Share by Company in 2025
Figure 34. Live Attenuated Polio Vaccine Revenue by Company in 2025 ($ millions)
Figure 35. Global Live Attenuated Polio Vaccine Revenue Market Share by Company in 2025
Figure 36. Global Live Attenuated Polio Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Live Attenuated Polio Vaccine Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 39. Americas Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 40. APAC Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 41. APAC Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 42. Europe Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 43. Europe Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Live Attenuated Polio Vaccine Sales 2021-2026 (K Dose)
Figure 45. Middle East & Africa Live Attenuated Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Americas Live Attenuated Polio Vaccine Sales Market Share by Country in 2025
Figure 47. Americas Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 48. Americas Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 49. Americas Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 50. United States Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Live Attenuated Polio Vaccine Sales Market Share by Region in 2025
Figure 55. APAC Live Attenuated Polio Vaccine Revenue Market Share by Region (2021-2026)
Figure 56. APAC Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 57. APAC Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 58. China Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. India Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Live Attenuated Polio Vaccine Sales Market Share by Country in 2025
Figure 66. Europe Live Attenuated Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 67. Europe Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 68. Europe Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 69. Germany Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. France Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Live Attenuated Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 77. Egypt Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Live Attenuated Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Live Attenuated Polio Vaccine in 2026
Figure 83. Manufacturing Process Analysis of Live Attenuated Polio Vaccine
Figure 84. Industry Chain Structure of Live Attenuated Polio Vaccine
Figure 85. Channels of Distribution
Figure 86. Global Live Attenuated Polio Vaccine Sales Market Forecast by Region (2027-2032)
Figure 87. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Live Attenuated Polio Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Live Attenuated Polio Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Live Attenuated Polio Vaccine Revenue Market Share Forecast by Application (2027-2032)
